Your response has been recorded.

Following the new Tecentriq approval for stage III dMMR colon cancer, which implementation challenge deserves the most attention?

• Ensuring timely MMR results before treatment decisions
• Managing drug budgets and payer authorisations
• Coordinating chemotherapy and immune-related toxicity monitoring
• Updating pathways across hospital and community oncology teams